Medscape2d
AAN 2025: Anticipating New Approaches in Myasthenia Gravis
Dr Nicholas Silvestri looks ahead to new data on existing agents and emerging therapies for myasthenia gravis.
Medscape2d
Conference MDAngle: AAN 2025
Dr Nicholas Silvestri shares AAN 2025 highlights, including anticipated presentations, quick takeaways, and insights on the ...
Argenx: The Magic May Be Already Priced In
Argenx is a hold due to limited catalysts in 2025, a rich valuation and clinical risk around label expansion. Read more about ...
The Pharma Letter4d
The week in pharma: action, reaction and insight – week to March 21
Important research news last week included UK pharma major AstraZeneca releasing encouraging results from the CALYPSO Phase ...
Immunovant price target raised to $61 from $58 at Stifel
Stifel analyst Alex Thompson raised the firm’s price target on Immunovant (IMVT) to $61 from $58 and keeps a Buy rating on the shares following yesterday’s topline data from the Batoclimab Myasthtenia ...